SYNAGEVA BIOPHARMA CORP's ticker is GEVA and the CUSIP is 87159A103. A total of 120 filers reported holding SYNAGEVA BIOPHARMA CORP in Q3 2014. The put-call ratio across all filers is 2.08 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2015 | $1,657,000 | +10.1% | 16,994 | +4.8% | 0.01% | +16.7% |
Q4 2014 | $1,505,000 | +33.4% | 16,220 | -1.1% | 0.01% | +20.0% |
Q3 2014 | $1,128,000 | -34.5% | 16,395 | -0.2% | 0.01% | -28.6% |
Q2 2014 | $1,722,000 | +35.9% | 16,434 | +7.6% | 0.01% | +16.7% |
Q1 2014 | $1,267,000 | +31.7% | 15,269 | +2.7% | 0.01% | +50.0% |
Q4 2013 | $962,000 | +12.1% | 14,865 | +9.6% | 0.00% | 0.0% |
Q3 2013 | $858,000 | -35.4% | 13,557 | -57.1% | 0.00% | -42.9% |
Q2 2013 | $1,328,000 | – | 31,609 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Baker Brothers Advisors | 9,223,182 | $387,189,000 | 7.66% |
EMERALD MUTUAL FUND ADVISERS TRUST | 78,486 | $3,295,000 | 0.56% |
COLUMBIA WANGER ASSET MANAGEMENT LLC | 2,485,288 | $104,382,000 | 0.46% |
HARVEY CAPITAL MANAGEMENT INC | 34,800 | $1,460,000 | 0.45% |
EMERALD ADVISERS, LLC | 148,232 | $6,223,000 | 0.38% |
DRIEHAUS CAPITAL MANAGEMENT LLC | 148,411 | $6,233,000 | 0.27% |
ArrowMark Colorado Holdings LLC | 15,500 | $651,000 | 0.18% |
CR Intrinsic Investors, LLC | 118,161 | $4,963,000 | 0.17% |
BB BIOTECH AG | 53,549 | $2,248,000 | 0.16% |
TURNER INVESTMENTS LLC | 209,744 | $8,806,000 | 0.12% |